BC Cancer Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion

Protocol Code:	*GIAVFL*
Tumour Group:	*Gastrointestinal*
Contact Physician:	*GI Systemic Therapy*

ELIGIBILITY:
- Locally advanced, locally recurrent or metastatic colorectal adenocarcinoma, not curable with surgery or radiation
- ECOG performance status less than or equal to 2

EXCLUSIONS:
- Suspected dihydropyrimidine dehydrogenase (DPD) deficiency (see Precautions)

CAUTIONS:
- Adequate marrow reserve, renal and liver function
- Patients with recent MI, uncontrolled angina, hypertension, cardiac arrhythmias, congestive heart failure or other serious medical illness
- Patients with baseline greater than 3 loose BM per day (in patients without colostomy or ileostomy)

TESTS AND MONITORING:

- **Baseline:** CBC and differential, platelets, Creatinine, LFTs (Bilirubin, ALT, Alkaline Phosphatase), *DPYD* test (not required if previously tested, or tolerated fluorouracil or capecitabine), appropriate imaging study. Optional : CEA and CA 19-9
- **Prior to each cycle**: CBC and differential, platelets
- **Prior to each even numbered cycle**: LFTs (Bilirubin, ALT, Alkaline Phosphatase), Creatinine
- For patients on warfarin, weekly INR during fluorouracil therapy until stable warfarin dose established, then INR prior to each cycle.
- Quantitative evaluation of disease response status every eight to twelve weeks; discontinue therapy if any progression of disease.
- If clinically indicated: CEA, CA 19-9

PREMEDICATIONS:
- Antiemetics are not usually required (see SCNAUSEA)

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use

TREATMENT:

A cycle equals:

Drug	Dose	BC Cancer Administration Guidelines
leucovorin	400 mg/m^2	IV in 250 ml D5W over 1 hour 30 min
fluorouracil	400 mg/m^2	IV push, after leucovorin, THEN
fluorouracil	2400 mg/m^2	IV over 46 h in D5W to a total volume of 230 mL by continuous infusion at 5 mL/h via Baxter LV5 INFUSOR *

Repeat every 14 days until disease progression or unacceptable toxicity.

Infusional fluorouracil dose may be escalated to 3000 mg/m^2 at Cycle 3 if the patient has experienced less than or equal to Grade 2 toxicity.

* *A*lternative administration:

- For 3000 to 5500 mg dose **select INFUSOR per dose range below (doses outside** dose banding range are **prepared as ordered**)**:**

Dose Banding Range	Dose Band INFUSOR (mg)
Less than 3000 mg	Pharmacy to mix specific dose
3000 to 3400 mg	3200 mg
3401 to 3800 mg	3600 mg
3801 to 4200 mg	4000 mg
4201 to 4600 mg	4400 mg
4601 to 5000 mg	4800 mg
5001 to 5500 mg	5250 mg
Greater than 5500 mg	Pharmacy to mix specific dose

- Inpatients: 1200 mg/m^2/day in 1000 mL D5W by continuous infusion daily over 23 h for 2 days

Patients with PICC lines should have a weekly assessment of the PICC site for evidence of infection or thrombosis.

DOSE MODIFICATIONS:

Fluorouracil Dosing Based on DPYD Activity Score (DPYD-AS)
Refer to "Fluorouracil and Capecitabine Dosing Based on DPYD Activity Score (DPYD-AS)" on www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual.

Agent	Dose Level +1	Dose Level 0 (Starting Dose)	Dose Level –1	Dose Level –2	Dose Level –3
leucovorin*	400 mg/m^2	400 mg/m^2	400 mg/m^2	400 mg/m^2	Discontinue Therapy
fluorouracil IV push	400 mg/m^2	400 mg/m^2	320 mg/m^2	240 mg/m^2	Discontinue Therapy
fluorouracil infusion	3000 mg/m^2	2400 mg/m^2	2000 mg/m^2	1600 mg/m^2	Discontinue Therapy

If IV push fluorouracil is delayed/omitted, leucovorin may also be delayed/omitted or reduced to 20 mg/m^2 IV push

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use

A. Dose Modifications for HEMATOLOGIC Toxicity

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles
	Grade	**ANC (x10^9/L)**	**fluorouracil**
▪ If ANC less than 1.0 on Day 1of cycle, hold treatment. Perform weekly CBC, maximum of 2 times. ▪ If ANC is greater than or equal to 1.0 within 2 weeks of initial treatment delay, proceed with treatment at the dose level noted across from the **lowest ANC** result of the delayed week(s). ▪ If ANC remains less than 1.0 after 2 weeks, discontinue treatment.	1	greater than or equal to 1.5	Maintain dose level
	2	1.0 to less than 1.5	Maintain dose level
	3	0.5 to less than 1.0	↓ 1 dose level
	4	less than 0.5	↓ 1 dose level
	Grade 4 neutropenia & greater than or equal to **Grade 2 fever**		↓ 1 dose level
	Grade	**Platelets (x10^9/L)**	**fluorouracil**
▪ If platelets less than 75 on Day 1 of cycle, hold treatment. Perform weekly CBC, maximum of 2 times. ▪ If platelets greater than or equal to 75 within 2 weeks of initial treatment delay, proceed with treatment at the dose level noted across from the **lowest platelets** result of the delayed week(s). ▪ If platelets remain less than 75 after 2 weeks, discontinue treatment.	1	greater than or equal to 75	Maintain dose level
	2	50 to less than 75	Maintain dose level
	3	10 to less than 50	Maintain dose level
	4	less than 10	Maintain dose level

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use

B. Dose Modifications for NON-HEMATOLOGIC Toxicity

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles
	Grade	**Diarrhea**	**fluorouracil**
▪ If diarrhea greater than or equal to Grade 2 on Day 1 of cycle, hold treatment. Perform weekly checks, maximum 2 times. ▪ If diarrhea is less than Grade 2 within 2 weeks of treatment delay, proceed with treatment at the dose level noted across from the **highest** Grade experienced. ▪ If diarrhea remains greater than or equal to Grade 2 after 2 weeks, discontinue treatment.	1	Increase of 2-3 stools/day, or mild increase in loose watery colostomy output	Maintain dose level
	2	Increase of 4-6 stools, or nocturnal stools or mild increase in loose watery colostomy output	Maintain dose level
	3	Increase of 7-9 stools/day or incontinence, malabsorption; or severe increase in loose watery colostomy output	↓ 1 dose level of
	4	Increase of 10 or more stools/day or grossly bloody colostomy output or loose watery colostomy output requiring parenteral support; dehydration	↓ 1 dose level
	Grade	**Stomatitis**	**fluorouracil**
▪ If stomatitis greater than or equal to Grade 2 on Day 1 of cycle, hold treatment. Perform weekly checks, maximum 2 times. ▪ If stomatitis is less than Grade 2 within 2 weeks of initial treatment delay, proceed with treatment at the dose level noted across from the **highest** Grade experienced. ▪ If stomatitis remains greater than or equal to Grade 2 after 2 weeks, discontinue treatment.	1	Painless ulcers, erythema or mild soreness	Maintain dose level
	2	Painful erythema, edema, or ulcers but can eat	Maintain dose level
	3	Painful erythema, edema, ulcers, and cannot eat	↓ 1 dose level
	4	As above but mucosal necrosis and/or requires enteral support, dehydration	↓ 2 dose levels

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use

PRECAUTIONS:

1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. Myocardial ischemia and angina occurs rarely in patients receiving fluorouracil or capecitabine. Development of cardiac symptoms including signs suggestive of ischemia or of cardiac arrhythmia is an indication to discontinue treatment. If there is development of cardiac symptoms patients should have urgent cardiac assessment. Generally re-challenge with either fluorouracil or capecitabine is not recommended as symptoms potentially have a high likelihood of recurrence which can be severe or even fatal. Seeking opinion from cardiologists and oncologists with expert knowledge about fluorouracil / capecitabine toxicity is strongly advised under these circumstances. The toxicity should also be noted in the patient's allergy profile.
3. **Diarrhea:** Patients should report mild diarrhea that persists over 24 hours or moderate diarrhea (4 stools or more per day above normal, or a moderate increase in ostomy output). Mild diarrhea can be treated with loperamide (eg. IMODIUM®) following the manufacturer's directions or per the BC Cancer Guidelines for Management of Chemotherapy-Induced Diarrhea. Note that diarrhea may result in increased INR and the risk of bleeding in patients on warfarin.
4. **Dihydropyrimidine dehydrogenase (DPD) deficiency** may result in severe and unexpected toxicity – stomatitis, diarrhea, neutropenia, neurotoxicity – secondary to reduced drug metabolism. This deficiency is thought to be present in about 3% of the population.
5. **Stomatitis**: Sucking ice chips may be considered for patients experiencing stomatitis. Remove dentures and place ice chips in mouth five minutes before chemotherapy. Continuously swish in mouth for 30 minutes, replenishing as ice melts. This may cause numbness or headaches, which subside quickly.
6. **Possible drug interaction with fluorouracil and warfarin** has been reported and may occur at any time. For patients on warfarin, weekly INR during fluorouracil therapy is recommended until a stable warfarin dose is established. Thereafter, INR prior to each cycle. Consultation to cardiology/internal medicine should be considered if difficulty in establishing a stable warfarin dose is encountered. Upon discontinuation of fluorouracil, repeat INR weekly for one month.
7. **Possible drug interaction with fluorouracil and phenytoin and fosphenytoin** has been reported and may occur at any time. Close monitoring is recommended. Fluorouracil may increase the serum concentration of these two agents.

Call the GI Systemic Therapy physician at your regional cancer centre or the GI Systemic Therapy Chair Dr. Theresa Chan at (604) 930-2098 with any problems or questions regarding this treatment program.

REFERENCES:

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use